Publications

  1. Goldman JW, Bueno AM, Dooms C, Jhaveri K, de Miguel M, Piha-Paul SA, Unni N, Zick A, Mahipal A, Suga JM, Naltet C, Antonanzas M, Crown J, Bebchuk J, Eli LD, Lowenthal BH, Mahalingam D. Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial. Clin Lung Cancer. 2025 May; 26 (3):191-200.e1 Epub 2024 Dec 11
    View PubMed
  2. Chandra S, Halfdanarson TR, Carlson EE, Rabe KG, Mahipal A, Majumder S, Bamlet WR, Horibe M, Tella SH, Shariq O, Carr RM, Cleary SP, Oberg AL, Antwi SO. Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma. Endocr Relat Cancer. 2025 Apr 1; 32 (4) Epub 2025 Mar 01
    View PubMed
  3. Naleid N, Pawar O, Chakrabarti S, Jin Z, Mangla A, Mahipal A. Safety and Efficacy of Anti-Human Epidermal Growth Factor 2 Agents in the Treatment of Biliary Tract Cancers: A Systematic Review. JCO Precis Oncol. 2025 Apr; 9:e2400594 Epub 2025 Apr 16
    View PubMed
  4. Mahipal A, Bucheit L, Zhang N, Barnett RM, Storandt MH, Chakrabarti S. Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers. Oncologist. 2025 Mar 10; 30 (3)
    View PubMed
  5. Storandt MH, Shi Q, Eng C, Lieu C, George T, Stoppler MC, Mauer E, Yilma B, Fragkogianni S, Teslow EA, Mahipal A, Jin Z. Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations. Cancers (Basel). 2025 Feb 28; 17 (5)
    View PubMed
  6. Shroff RT, King G, Colby S, Scott AJ, Borad MJ, Goff L, Matin K, Mahipal A, Kalyan A, Javle MM, El Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley RK, Thumar J, El-Khoueiry A, Guthrie KA, Chiorean EG, Hochster H, Philip PA. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. J Clin Oncol. 2025 Feb 10; 43 (5):536-544 Epub 2024 Dec 13
    View PubMed
  7. Naing A, Mahipal A, Javle M, Wang J, Bauer TM, Bajor DL, Elias AD, Shields A, Davis E, Chawla S, Safran H, Powderly JD, D'Amato G, Meyer CF, Tang X, Yao S, Keegan P. Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study. J Immunother Precis Oncol. 2025 Feb; 8 (1):71-81 Epub 2025 Jan 15
    View PubMed
  8. Norman A, Seetharam M, Allred J, Kong J, Opyrchal M, Ma WW, Lou Y, Dy GK, Mahipal A, Weroha SJ, Wahner Hendrickson AE, Reid JM, Adjei AA. A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors. BJC Rep. 2025 Jan 14; 3 (1):1
    View PubMed
  9. Marell P, Kournoutas I, Gile J, Peersen A, Shah P, Babiker H, Kankeu LF, Washburn L, Graham R, Truty M, Starlinger P, Halfdanarson T, Jin Z, Jatoi A, McWilliams R, Borad M, Bekaii-Saab TS, Mahipal A, Ou FS, Tran NH. Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience. Oncologist. 2024 Dec 14 [Epub ahead of print]
    View PubMed
  10. Siripoon T, O'Donnell C, Jin Z, Mahipal A. Fibroblast growth factor therapies in biliary tract cancers: current and future state. Expert Opin Investig Drugs. 2024 Dec; 33 (12):1245-1255 Epub 2024 Dec 04
    View PubMed
  11. Storandt MH, Zemla TJ, Patell K, Naleid N, Gile JJ, Tran NH, Chakrabarti S, Jin Z, Borad M, Mahipal A. Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study. Oncologist. 2024 Nov 4; 29 (11):986-996
    View PubMed
  12. Van Treeck BJ, Olave MC, Watkins RD, Lu H, Moreira RK, Mounajjed T, Johnson MJ, Smith CY, Ilyas SI, Tran NH, Jenkins SM, Reed KA, Smoot R, Mahipal A, Allende D, Graham RP. Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma. HPB (Oxford). 2024 Jul; 26 (7):938-948 Epub 2024 Apr 23
    View PubMed
  13. O'Donnell CDJ, Naleid N, Siripoon T, Zablonski KG, Storandt MH, Selfridge JE, Hallemeier CL, Conces ML, Jethwa KR, Bajor DL, Thiels CA, Warner SG, Starlinger PP, Atwell TD, Mitchell JL, Mahipal A, Jin Z. Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer. Cancers (Basel). 2024 Jun 29; 16 (13) Epub 2024 June 29
    View PubMed
  14. Desai A, Xiao AH, Choi D, Toruner MD, Walden D, Halfdanarson TR, Alberts S, McWilliams RR, Mahipal A, Ahn D, Babiker H, Stybayeva G, Revzin A, Kizilbash S, Adjei A, Bekaii-Saab T, Mansfield AS, Carr RM, Ma WW. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2024 May 13; 16 (10)
    View PubMed
  15. Mahipal A, Storandt MH, Teslow EA, Jaeger E, Stoppler MC, Jin Z, Chakrabarti S. Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies. Cancers (Basel). 2024 May 10; 16 (10)
    View PubMed
  16. Van Treeck BJ, Olave MC, Watkins RD, Lu H, Moreira RK, Mounajjed T, Johnson MJ, Smith CY, Ilyas SI, Tran NH, Jenkins SM, Reed KA, Smoot R, Mahipal A, Allende D, Graham RP. WITHDRAWN: Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma. HPB (Oxford). 2024 Apr 24 [Epub ahead of print]
    View PubMed
  17. Patell K, Mears VL, Storandt MH, Mahipal A. Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer. Expert Opin Drug Metab Toxicol. 2024 Apr; 20 (4):197-205 Epub 2024 Mar 20
    View PubMed
  18. Rappaport AR, Kyi C, Lane M, Hart MG, Johnson ML, Henick BS, Liao CY, Mahipal A, Shergill A, Spira AI, Goldman JW, Scallan CD, Schenk D, Palmer CD, Davis MJ, Kounlavouth S, Kemp L, Yang A, Li YJ, Likes M, Shen A, Boucher GR, Egorova M, Veres RL, Espinosa JA, Jaroslavsky JR, Kraemer Tardif LD, Acrebuche L, Puccia C, Sousa L, Zhou R, Bae K, Hecht JR, Carbone DP, Johnson B, Allen A, Ferguson AR, Jooss K. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2024 Apr; 30 (4):1013-1022 Epub 2024 Mar 27
    View PubMed
  19. Lenz HJ, Parikh A, Spigel DR, Cohn AL, Yoshino T, Kochenderfer M, Elez E, Shao SH, Deming D, Holdridge R, Larson T, Chen E, Mahipal A, Ucar A, Cullen D, Baskin-Bey E, Kang T, Hammell AB, Yao J, Tabernero J. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer. 2024 Mar 13; 12 (3)
    View PubMed
  20. Storandt MH, Tella SH, Wieczorek MA, Hodge D, Elrod JK, Rosenberg PS, Jin Z, Mahipal A. Projected Incidence of Hepatobiliary Cancers and Trends Based on Age, Race, and Gender in the United States. Cancers (Basel). 2024 Feb 6; 16 (4) Epub 2024 Feb 06
    View PubMed
  21. Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klumpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Komatsu Y, Ahn DH, Epstein RS, Halim AB, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA, FOENIX-CCA2 Study Investigators. Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer. Future Oncol 2024; 20 (36):2811-2822 Epub 2024 June 17
    View PubMed
  22. Storandt MH, Jin Z, Mahipal A. Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date. Onco Targets Ther. 2024; 17:383-394 Epub 2024 May 17
    View PubMed
  23. Emiloju OE, Storandt M, Zemla T, Tran N, Jethwa K, Mahipal A, Mitchell J, Thiels C, Mathis K, McWilliams R, Hubbard J, Sinicrope F, Shi Q, Jin Z. Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer. JCO Precis Oncol. 2024 Jan; 8:e2300127
    View PubMed
  24. Washburn L, Mahipal A, Jatoi A, Kottschade L, Tran N. Postpartum related intrahepatic cholangiocarcinoma with FGFR2 fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and review. J Gastrointest Oncol. 2023 Dec 31; 14 (6):2627-2636 Epub 2023 Dec 12
    View PubMed
  25. Hassan H, Chakrabarti S, Zemla T, Yin J, Wookey V, Prasai K, Abdellatief A, Katta R, Tran N, Jin Z, Cleary S, Roberts L, Mahipal A. Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection. Eur J Surg Oncol. 2023 Nov; 49 (11):106994 Epub 2023 July 27
    View PubMed
  26. Storandt MH, Kurniali PC, Mahipal A, Jin Z. Targeted Therapies in Advanced Cholangiocarcinoma. Life (Basel). 2023 Oct 16; 13 (10)
    View PubMed
  27. Palmer ME, Gile JJ, Storandt MH, Jin Z, Zemla TJ, Tran NH, Mahipal A. Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study. Cancers (Basel). 2023 Oct 6; 15 (19) Epub 2023 Oct 06
    View PubMed
  28. Tella SH, Foster N, Qian S, Nguyen T, Borad MJ, McWilliams RR, Alberts SR, Wee Ma W, Chakrabarti S, Fruth B, Wessling J, Hartgers M, Washburn L, Fernandez-Zapico ME, Hogenson TL, Pitot H, Jin Z, Mahipal A. Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist. 2023 Oct 3; 28 (10):917-e966
    View PubMed
  29. Maithel SK, Keilson JM, Cao HST, Rupji M, Mahipal A, Lin BS, Javle MM, Cleary SP, Akce M, Switchenko JM, Rocha FG. ASO Visual Abstact: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023 Oct; 30 (11):6569-6570
    View PubMed
  30. Maithel SK, Keilson JM, Cao HST, Rupji M, Mahipal A, Lin BS, Javle MM, Cleary SP, Akce M, Switchenko JM, Rocha FG. NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023 Oct; 30 (11):6558-6566 Epub 2023 June 27
    View PubMed
  31. Chakrabarti S, Grewal US, Vora KB, Parikh AR, Almader-Douglas D, Mahipal A, Sonbol MBB. Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review. JCO Precis Oncol. 2023 Aug; 7:e2300182
    View PubMed
  32. Coston T, Desai A, Babiker H, Sonbol MB, Chakrabarti S, Mahipal A, McWilliams R, Ma WW, Bekaii-Saab TS, Stauffer J, Starr JS. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience. JCO Precis Oncol. 2023 Aug; 7:e2200706
    View PubMed
  33. Storandt MH, Rogen KR, Iyyangar A, Schnell RR, Mitchell JL, Hubbard JM, Sinicrope FA, Jatoi A, Mahipal A, Shi Q, Jin Z. Completion of Genetic Testing and Incidence of Pathogenic Germline Mutation among Patients with Early-Onset Colorectal Cancer: A Single Institution Analysis. Cancers (Basel). 2023 Jul 11; 15 (14) Epub 2023 July 11
    View PubMed
  34. Quintanilha JCF, Storandt MH, Graf RP, Li G, Keller R, Lin DI, Ross JS, Huang RSP, Schrock AB, Oxnard GR, Chakrabarti S, Mahipal A. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness. JCO Precis Oncol. 2023 Jul; 7:e2300092
    View PubMed
  35. Perera ND, Bellomo TR, Schmidt WM, Litt HK, Shyu M, Stavins MA, Wang MM, Bell A, Saleki M, Wolf KI, Ionescu R, Tao JJ, Ji S, O'Keefe RM, Pun M, Takasugi JM, Steinberg JR, Go RS, Turner BE, Mahipal A. Analysis of Female Participant Representation in Registered Oncology Clinical Trials in the United States from 2008 to 2020. Oncologist. 2023 Jun 2; 28 (6):510-519
    View PubMed
  36. Tella SH, Mara K, Chakrabarti S, Jin Z, Mahipal A. A glimpse into the future of esophageal carcinoma in the United States: predicting the future incidence until 2040 based on the current epidemiological data. J Gastrointest Oncol. 2023 Feb 28; 14 (1):1-10 Epub 2023 Feb 23
    View PubMed
  37. Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klumpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA, FOENIX-CCA2 Study Investigators. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 2023 Jan 19; 388 (3):228-239
    View PubMed
  38. Grotz TE, Yonkus JA, Thiels CA, Warner SG, McWilliams RR, Mahipal A, Bekaii-Saab TS, Cleary SP, Kendrick ML, Truty MJ. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot Study. Ann Surg Oncol. 2023 Jan; 30 (1):395-403 Epub 2022 Aug 16
    View PubMed
  39. Mahipal A, Palmer M, Gile J, Kim R. Durvalumab: a pd-l1 blocking antibody for the treatment of adult patients with locally advanced or metastatic biliary tract cancer. European Oncology and Haematology. 2023; 19 (1):22-6
  40. Tella SH, Mahipal A. An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma. Expert Opin Pharmacother. 2022 Dec; 23 (17):1879-1885 Epub 2022 Oct 20
    View PubMed
  41. Storandt MH, Jin Z, Mahipal A. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion. Expert Rev Anticancer Ther. 2022 Dec; 22 (12):1265-1274 Epub 2022 Nov 23
    View PubMed
  42. Hogenson TL, Xie H, Phillips WJ, Toruner MD, Li JJ, Horn IP, Kennedy DJ, Almada LL, Marks DL, Carr RM, Toruner M, Sigafoos AN, Koenig-Kappes AN, Olson RL, Tolosa EJ, Zhang C, Li H, Doles JD, Bleeker J, Barrett MT, Boyum JH, Kipp BR, Mahipal A, Hubbard JM, Scheffler Hanson TJ, Petersen GM, Dasari S, Oberg AL, Truty MJ, Graham RP, Levy MJ, Zhu M, Billadeau DD, Adjei AA, Dusetti N, Iovanna JL, Bekaii-Saab TS, Ma WW, Fernandez-Zapico ME. Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers. JCI Insight. 2022 Nov 22; 7 (22)
    View PubMed
  43. Storandt MH, Gile JJ, Palmer ME, Zemla TJ, Ahn DH, Bekaii-Saab TS, Jin Z, Tran NH, Mahipal A. Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. Cancers (Basel). 2022 Oct 22; 14 (21)
    View PubMed
  44. Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Gandhi L, Ghosh A, Hickman D, Gallacher PD, Wennborg A, Attar EC, Awad MM, Das S, Dumbrava EE. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open. 2022 Oct; 7 (5):100573 Epub 2022 Sept 07
    View PubMed
  45. Gile JJ, Wookey V, Zemla TJ, Shi Q, Jin Z, Alberts SR, McWilliams RR, Ma WW, Borad M, Bekaii-Saab TS, Tran NH, Mahipal A. Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma. Target Oncol. 2022 Sep; 17 (5):529-538 Epub 2022 Sept 02
    View PubMed
  46. Uson Junior PLS, DeLeon TT, Bogenberger JM, Pai RK, Kosiorek HE, Yin J, Ahn DH, Sonbol MB, Bekaii-Saab T, Mansfield AS, Buetow K, Gores GJ, Smoot R, Vasmatzis G, Kipp BR, Mahipal A, Baker AT, Babiker H, Barro O, Dumbauld C, Zhou Y, Aslam FN, Barrett M, Jacobs B, Meurice N, Arora M, Petit J, Elliott N, Nagalo B, Salomao MA, Borad MJ. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Dig Dis Sci. 2022 Aug; 67(8):3797-3805. Epub 2021 Nov 13.
    View PubMed
  47. Palmer CD, Rappaport AR, Davis MJ, Hart MG, Scallan CD, Hong SJ, Gitlin L, Kraemer LD, Kounlavouth S, Yang A, Smith L, Schenk D, Skoberne M, Taquechel K, Marrali M, Jaroslavsky JR, Nganje CN, Maloney E, Zhou R, Navarro-Gomez D, Greene AC, Grotenbreg G, Greer R, Blair W, Cao MD, Chan S, Bae K, Spira AI, Roychowdhury S, Carbone DP, Henick BS, Drake CG, Solomon BJ, Ahn DH, Mahipal A, Maron SB, Johnson B, Rousseau R, Yelensky R, Liao CY, Catenacci DVT, Allen A, Ferguson AR, Jooss K. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2022 Aug; 28 (8):1619-1629 Epub 2022 Aug 15
    View PubMed
  48. Desai AP, Scheckel CJ, Soderberg LC, Jensen CJ, Orme JJ, Tella SH, Kommalapati A, Pritchett JC, Khera N, Mahipal A, Go RS, Mayo Clinic Hematology and ONcology Outcomes Research (HONOR) Group. Economic Cost and Sustainability of Oral Therapies in Precision Oncology. JCO Oncol Pract. 2022 Aug; 18 (8):e1247-e1254 Epub 2022 May 26
    View PubMed
  49. Perera ND, Kamceva M, Shen JZ, Turner BE, Abdou M, Steinberg JR, Mahipal A. Analysis of Registered Clinical Trials in Gastroenterology, 2007-2019. JAMA Netw Open. 2022 Jul 1; 5 (7):e2221770 Epub 2022 July 01
    View PubMed
  50. Chakrabarti S, Kasi AK, Parikh AR, Mahipal A. Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC). Cancers (Basel). 2022 Jun 23; 14 (13) Epub 2022 June 23
    View PubMed
  51. Tella SH, Kommalapati A, Mahipal A, Jin Z. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Biomedicines. 2022 Jun 2; 10 (6) Epub 2022 June 02
    View PubMed
  52. Liddell SS, Chakrabarti S, Wintheiser GA, Zemla TJ, Shi Q, Tella SH, Jin Z, Wookey VB, Hassan H, Tran NH, Borad MJ, Mahipal A. Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precis Oncol. 2022 Jun; 6:e2200003.
    View PubMed
  53. Chakrabarti S, Kamgar M, Mahipal A. Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. Cancers (Basel). 2022 May 24; 14 (11)
    View PubMed
  54. Thompson SM, Suman G, Torbenson MS, Chen ZE, Jondal DE, Patra A, Ehman EC, Andrews JC, Fleming CJ, Welch BT, Kurup AN, Roberts LR, Watt KD, Truty MJ, Cleary SP, Smoot RL, Heimbach JK, Tran NH, Mahipal A, Yin J, Zemla T, Wang C, Fogarty Z, Jacobson M, Kemp BJ, Venkatesh SK, Johnson GB, Woodrum DA, Goenka AH. PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68) Ga-PSMA-11 PET Using Cyclotron-Produced (68) Ga. Hepatol Commun. 2022 May; 6 (5):1172-1185 Epub 2021 Nov 15
    View PubMed
  55. Wintheiser G, Zemla T, Mahipal A. Reply to F. Nichetti et al. JCO Precis Oncol 2022 Apr; 6:e2200131
    View PubMed
  56. Alva-Ruiz R, Yohanathan L, Yonkus JA, Abdelrahman AM, Gregory LA, Halfdanarson TR, Mahipal A, McWilliams RR, Ma WW, Hallemeier CL, Graham RP, Grotz TE, Smoot RL, Cleary SP, Nagorney DM, Kendrick ML, Truty MJ. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2022 Mar; 29 (3):1579-1591 Epub 2021 Nov 01
    View PubMed
  57. Ahn DH, Uson Junior PLS, Masci P, Kosiorek H, Halfdanarson TR, Mody K, Babiker H, DeLeon T, Sonbol MB, Gores G, Smoot R, Bekaii-Saab T, Mahipal A, Mansfield A, Tran NH, Hubbard JM, Borad MJ. A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. Invest New Drugs. 2022 Feb; 40 (1):134-141 Epub 2021 Aug 31
    View PubMed
  58. Wong BO, Perera ND, Shen JZ, Turner BE, Litt HK, Mahipal A, Wren SM. Analysis of Registered Clinical Trials in Surgical Oncology, 2008-2020. JAMA Netw Open. 2022 Jan 4; 5 (1):e2145511 Epub 2022 Jan 04
    View PubMed
  59. Kankeu Fonkoua LA, Serrano Uson Junior PL, Mody K, Mahipal A, Borad MJ, Roberts LR. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opin Ther Targets. 2022 Jan; 26 (1):79-92 Epub 2022 Jan 24
    View PubMed
  60. Storandt MH, Mahipal A, Tella SH, Kommalapati A, Jin Z. Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations. J Hepatocell Carcinoma. 2022; 9:1187-1200 Epub 2022 Nov 29
    View PubMed
  61. Goldman J, Dooms C, Jhaveri K, de Miguel MJ, Piha-Paul SA, Unni N, Mahipal A, Suga JM, Naltet C, Zick A, Crown J, Chae YK, DiPrimeo D, Eli LD, McCulloch L, Mahalingam D. Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: findings from the SUMMIT basket trial. European Journal of Cancer. 2022; 174:S82
  62. Wintheiser G, Zemla T, Shi Q, Tran N, Prasai K, Tella SH, Mody K, Ahn D, Borad M, Bekaii-Saab T, Mahipal A. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. JCO Precis Oncol. 2022 Jan; 6:e2100156
    View PubMed
  63. Chakrabarti S, Finnes HD, Mahipal A. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management. Expert Opin Drug Metab Toxicol. 2022 Jan; 18 (1):85-98 Epub 2022 Feb 12
    View PubMed
  64. Jin Z, Dixon JG, Fiskum JM, Parekh HD, Sinicrope FA, Yothers G, Allegra CJ, Wolmark N, Haller D, Schmoll HJ, de Gramont A, Kerr R, Taieb J, Van Cutsem E, Tweleves C, O'Connell M, Saltz LB, Sadahiro S, Blanke CD, Tomita N, Seitz JF, Erlichman C, Yoshino T, Yamanaka T, Marsoni S, Andre T, Mahipal A, Goldberg RM, George TJ, Shi Q. Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. J Natl Cancer Inst. 2021 Nov 29; 113 (12):1693-1704
    View PubMed
  65. Gits HC, Tang AH, Harmsen WS, Bamlet WR, Graham RP, Petersen GM, Smyrk TC, Mahipal A, Kowalchuk RO, Ashman JB, Rule WG, Owen D, Neben Wittich MA, McWilliams RR, Halfdanarson T, Ma WW, Sio TT, Cleary SP, Truty MJ, Haddock MG, Hallemeier CL, Merrell KW. Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy. J Gastrointest Oncol. 2021 Oct; 12 (5):2275-2286
    View PubMed
  66. Ueberroth BE, Liu AJ, Graham RP, Bekaii-Saab TS, McWilliams RR, Mahipal A, Truty MJ, Mody K, Sonbol MB, Halfdanarson TR. Osteoclast-Like Giant Cell Tumors of the Pancreas: Clinical Characteristics, Genetic Testing, and Treatment Modalities. Pancreas. 2021 Aug 1; 50 (7):952-956
    View PubMed
  67. Chakrabarti S, Wintheiser G, Tella SH, Oxencis C, Mahipal A. TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies. Pharmacol Ther. 2021 Aug; 224:107823 Epub 2021 Mar 02
    View PubMed
  68. Tran NH, Foster NR, Mahipal A, Byrne T, Hubbard J, Silva A, Mody K, Alberts S, Borad MJ. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Invest New Drugs. 2021 Aug; 39 (4):1072-1080 Epub 2021 Mar 01
    View PubMed
  69. Kommalapati A, Tella SH, Borad M, Javle M, Mahipal A. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers (Basel). 2021 Jun 13; 13 (12) Epub 2021 June 13
    View PubMed
  70. Cox RE Jr, Mahipal A, Chakrabarti S. A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy. Cureus. 2021 Apr 22; 13 (4):e14640
    View PubMed
  71. Aitcheson G, Mahipal A, John BV. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? Expert Opin Investig Drugs. 2021 Apr; 30 (4):463-477 Epub 2021 Apr 11
    View PubMed
  72. Prasai K, Tella SH, Yadav S, Kommalapati A, Mara K, Mady M, Hassan MA, Wongjarupong N, Rodriguez-Payan N, Borad M, Patel T, Roberts LR, Mahipal A. Aspirin and Statin Use and the Risk of Gallbladder Cancer. Cancers (Basel). 2021 Mar 9; 13 (5) Epub 2021 Mar 09
    View PubMed
  73. Patel SR, Saliba AN, Steel S, Liewluck T, Mahipal A. Metastatic Colon Cancer Presenting With Immune-mediated Necrotizing Myopathy. Clin Colorectal Cancer. 2021 Mar; 20 (1):e71-e73 Epub 2020 Aug 29
    View PubMed
  74. Tella SH, Kommalapati A, Mahipal A. Systemic therapy for advanced hepatocellular carcinoma: targeted therapies. Chin Clin Oncol. 2021 Feb; 10 (1):10 Epub 2020 May 14
    View PubMed
  75. Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, Goenka AH, Hallemeier CL, Haddock MG, Harmsen WS, Mahipal A, McWilliams RR, Halfdanarson TR, Grothey AF. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Ann Surg. 2021 Feb 1; 273 (2):341-349
    View PubMed
  76. Breen WG, Jethwa KR, Yu NY, Spears GM, Harmsen WS, Miller RC, Ashman JB, Rule WG, Sio TT, Neben-Wittich MA, Haddock MG, Mahipal A, Truty MJ, Hallemeier CL, Merrell KW. Patient-Reported Quality of Life Before and After Chemoradiation for Intact Pancreas Cancer: A Prospective Registry Study. Pract Radiat Oncol. 2021 Jan-Feb; 11 (1):e63-e69 Epub 2020 July 23
    View PubMed
  77. Kowalchuk RO, Lester SC, Graham RP, Harmsen WS, Zhang L, Halfdanarson TR, Smoot RL, Gits HC, Ma WW, Owen D, Mahipal A, Miller RC, Wittich MAN, Cleary SP, McWilliams RR, Haddock MG, Hallemeier CL, Truty MJ, Merrell KW. Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9. Front Oncol. 2021; 11:651119 Epub 2021 May 11
    View PubMed
  78. Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol. 2021; 5 Epub 2021 July 28
    View PubMed
  79. Antwi SO, Bamlet WR, Cawthon RM, Rabe KG, Druliner BR, Sicotte H, Jatoi A, Mahipal A, Boardman LA, Oberg AL, Petersen GM. Shorter Treatment-Naive Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2021 Jan; 30 (1):210-216 Epub 2020 Nov 13
    View PubMed
  80. Yu J, Mahipal A, Kim R. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. Onco Targets Ther. 2021; 14:5145-5160 Epub 2021 Oct 23
    View PubMed
  81. Kim R, Tan E, Wang E, Mahipal A, Chen DT, Cao B, Masawi F, Machado C, Yu J, Kim DW. A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. Oncologist. 2020 Dec; 25 (12):e1893-e1899 Epub 2020 Sept 14
    View PubMed
  82. Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2020 Dec 1; 6 (12):e204930 Epub 2020 Dec 10
    View PubMed
  83. Tella SH, Kommalapati A, Alberts SR, McWilliams R, Mahipal A. Collateral damage of COVID-19 pandemic on oncology clinical trials. Chin Clin Oncol 2020 Dec; 9 (6):80 Epub 2020 Nov 18
    View PubMed
  84. Jethwa KR, Sannapaneni S, Mullikin TC, Harmsen WS, Petersen MM, Antharam P, Laughlin B, Mahipal A, Halfdanarson TR, Merrell KW, Neben-Wittich M, Sio TT, Haddock MG, Hallemeier CL. Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer. J Gastrointest Oncol. 2020 Dec; 11 (6):1408-1420
    View PubMed
  85. Xie H, Liu J, Yin J, Ogden JR, Mahipal A, McWilliams RR, Truty MJ, Bekaii-Saab TS, Petersen GM, Jatoi A, Hubbard JM, Ma WW. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Oncologist. 2020 Nov; 25 (11):e1681-e1690 Epub 2020 Aug 04
    View PubMed
  86. Mahipal A, Tella SH, Kommalapati A, Yu J, Kim R. Prevention and treatment of FGFR inhibitor-associated toxicities. Crit Rev Oncol Hematol. 2020 Nov; 155:103091 Epub 2020 Sept 01
    View PubMed
  87. Mady M, Prasai K, Tella SH, Yadav S, Hallemeier CL, Rakshit S, Roberts L, Borad M, Mahipal A. Neutrophil to lymphocyte ratio as a prognostic marker in metastatic gallbladder cancer. HPB (Oxford). 2020 Oct; 22 (10):1490-1495 Epub 2020 Feb 28
    View PubMed
  88. Chakrabarti S, Xie H, Urrutia R, Mahipal A. The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review. Cancers (Basel). 2020 Sep 29; 12(10).
    View PubMed
  89. Chakrabarti S, Peterson CY, Sriram D, Mahipal A. Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World J Gastrointest Oncol. 2020 Aug 15; 12 (8):808-832
    View PubMed
  90. Xie H, Liu J, Ogden JR, Yin J, Jatoi A, Hubbard JM, McWilliams RR, Mahipal A, Petersen GM, Bekaii-Saab TS, Ma WW. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Am J Clin Oncol. 2020 Aug; 43 (8):586-590
    View PubMed
  91. Chakrabarti S, Kamgar M, Mahipal A. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm. Cancers (Basel). 2020 Jul 24; 12 (8) Epub 2020 July 24
    View PubMed
  92. Kim RD, Azad NS, Morse MA, Poplin E, Mahipal A, Tan B Jr, Mavroukakis SA, Fantini M, Tsang KY, Zaki A, Torrealba J, Arlen PM, Beg MS. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul 15; 26 (14):3557-3564 Epub 2020 Apr 17
    View PubMed
  93. Abdallah MA, Wongjarupong N, Hassan MA, Taha W, Abdalla A, Bampoh S, Onyirioha K, Nelson M, Glubranson LA, Wiseman GA, Fleming CJ, Andrews JC, Mahipal A, Roberts LR. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Expert Rev Gastroenterol Hepatol. 2020 Jul; 14 (7):619-629 Epub 2020 June 22
    View PubMed
  94. Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, Schell MJ, Zhou JM, Mahipal A, Kim BH, Kim DW. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol. 2020 Jun 1; 6 (6):888-894
    View PubMed
  95. Kommalapati A, Tella SH, Yadav S, Goyal G, Hallemeier C, Durgin L, Jin Z, Mahipal A. Survival and prognostic factors in patients with rectal squamous cell carcinoma. Eur J Surg Oncol. 2020 Jun; 46 (6):1111-1117 Epub 2020 Mar 04
    View PubMed
  96. Tella SH, Kommalapati A, Yadav S, Bergquist JR, Goyal G, Durgin L, Borad M, Cleary SP, Truty MJ, Mahipal A. Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. Eur J Surg Oncol. 2020 May; 46 (5):789-795 Epub 2020 Jan 11
    View PubMed
  97. Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, Bekaii-Saab TS, Mahipal A. Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist. 2020 May; 25 (5):380-e763 Epub 2019 Dec 11
    View PubMed
  98. Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, M Mohammad R, Philip PA. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2020 Mar 15; 26 (6):1338-1348 Epub 2019 Dec 12
    View PubMed
  99. Yadav S, Tella SH, Kommalapati A, Mara K, Prasai K, Mady MH, Hassan M, Smoot RL, Cleary SP, Truty MJ, Roberts LR, Mahipal A. A Novel Clinically Based Staging System for Gallbladder Cancer. J Natl Compr Canc Netw. 2020 Feb; 18 (2):151-159
    View PubMed
  100. Tella SH, Kommalapati A, Borad MJ, Mahipal A. Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 2020 Jan; 21 (1):e29-e41
    View PubMed
  101. Mody K, Kasi PM, Yang J, Surapaneni PK, Bekaii-Saab T, Ahn DH, Mahipal A, Sonbol MB, Starr JS, Roberts A, Nagy R, Lanman R, Borad MJ. Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. JCO Precis Oncol. 2019 Dec; 3:1-9
    View PubMed
  102. Hyman DM, Tran B, Paz-Ares L, Machiels JP, Schellens JH, Bedard PL, Campone M, Cassier PH, Saratopoulos J, Vaishampayan U, Chugh R, Mahipal A, Lockhart AC, Sessa C, Zander T, Ng M, Curigliano G, Bendiske J, Chen X, Choudhury S, Graus-Porta D, Lewis N, Perez JM, Jose M. Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. JCO Precision Oncology. 2019; 3.
  103. Huffman BM, Jin Z, Yadav S, Patel S, Nagorney DM, Truty MJ, McWilliams RR, Halfdanarson TR, Mahipal A. Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma. Clin Colorectal Cancer. 2019 Sep; 18 (3):218-225 Epub 2019 May 15
    View PubMed
  104. Tella SH, Kommalapati A, Yadav S, Bergquist JR, Truty MJ, Durgin L, Ma WW, Cleary SP, McWilliams RR, Mahipal A. Survival and prognostic factors in patients with pancreatic squamous cell carcinoma. Eur J Surg Oncol. 2019 Sep; 45 (9):1700-1705 Epub 2019 May 15
    View PubMed
  105. Mahipal A, Tella SH, Kommalapati A, Anaya D, Kim R. FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma. Cancer Treat Rev. 2019 Aug; 78:1-7 Epub 2019 June 22
    View PubMed
  106. Yadav S, Xie H, Bin-Riaz I, Sharma P, Bin-Riaz I, Durani U, Goyal G, Borah B, Borad MJ, Smoot RL, Roberts LR, Go RS, McWilliams RR, Mahipal A. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Eur J Surg Oncol. 2019 Aug; 45 (8):1432-1438 Epub 2019 Mar 21
    View PubMed
  107. Mahipal A, Tella SH, Kommalapati A, Lim A, Kim R. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel? Cancers (Basel). 2019 Jul 30; 11 (8) Epub 2019 July 30
    View PubMed
  108. Mahipal A, Ejadi S, Gnjatic S, Kim-Schulze S, Lu H, Ter Meulen JH, Kenney R, Odunsi K. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. Cancer Immunol Immunother. 2019 Jul; 68 (7):1211-1222 Epub 2019 May 08
    View PubMed
  109. Chakrabarti S, Tella SH, Kommalapati A, Huffman BM, Yadav S, Riaz IB, Goyal G, Mody K, Borad M, Cleary S, Smoot RL, Mahipal A. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Gastrointest Oncol. 2019 Jun; 10(3):554-561.
    View PubMed
  110. Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, Copolla D, Kim J, Kim R. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Invest New Drugs. 2019 Jun; 37 (3):473-481 Epub 2018 Oct 09
    View PubMed
  111. Xie H, Hogenson TL, Horn IP, Almada L, Marks D, Koenig A, Tolosa E, Barrett MT, Boyum JH, Mahipal A, Hubbard JM, Scheffler Hanson TJ, Yin J, Petersen GM, Revzin A, Billadeau DD, Bekaii-Saab TS, Adjei AA, Ma WW, Fernandez-Zapico M. Patient-derived organoid (pdo), a new personalized therapy selection tool for prompt clinical decision making in metastatic gastrointestinal (mgi) cancer patients Journal Of Clinical Oncology. 2019 May 20; 37(15):3101. Epub 2019 May 26.
  112. Chakrabarti S, Jin Z, Huffman BM, Yadav S, Graham RP, Lam-Himlin DM, Lightner AL, Hallemeier CL, Mahipal A. Local excision for patients with stage I anal canal squamous cell carcinoma can be curative. J Gastrointest Oncol. 2019 Apr; 10 (2):171-178
    View PubMed
  113. Sanhueza CT, Huffman BM, Jin Z, Hartgers ML, Smyrk TC, Westin G, McWilliams RR, Ma WW, Alberts SR, Mahipal A. Solid Pseudopapillary Neoplasms of the Pancreas: A Large American Cohort. Pancreas 2019 Apr; 48 (4):e21-e22
    View PubMed
  114. Mody K, Kasi PM, Yang JD, Surapaneni PK, Bekaii-Saab T, Ahn DH, Mahipal A, Sonbol MB, Starr JS, Roberts A, Nagy R, Lanman R, Borad MJ. Circulating tumor dna profiling of advanced biliary tract cancers JCO Precision Oncology. 2019 Mar 18; 3
  115. Kommalapati A, Tella SH, Goyal G, Borad M, Alberts SR, Roberts L, Hubbard JM, Durgin L, Cleary S, Mahipal A. Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. HPB (Oxford). 2019 Mar; 21 (3):379-386 Epub 2018 Sept 25
    View PubMed
  116. Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M. A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS One. 2019; 14 (9):e0221994 Epub 2019 Sept 17
    View PubMed
  117. Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G Jr, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag Res. 2019; 11:10463-10476 Epub 2019 Dec 13
    View PubMed
  118. Tella SH, Mahipal A, Kommalapati A, Jin Z. Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date. Onco Targets Ther. 2019; 12:10335-10342 Epub 2019 Nov 28
    View PubMed
  119. Mahipal A, Kommalapati A, Mehta R, Kim RD. Molecular-Targeted Therapies in Hepatocellular Carcinoma Hoshida Y editor.Hepatocellular Carcinoma: Translational Precision Medicine Approaches Cham (CH) Humana Press 2019225-238
    View PubMed
  120. Yadav S, Xie H, Riaz IB, Sharma P, Mahipal A, McWilliams R. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Ann Oncol. 2018 Oct; 29 Suppl 8:viii260-viii261
    View PubMed
  121. Mahipal A, Kommalapati A, Tella SH, Lim A, Kim R. Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opin Investig Drugs. 2018 Sep; 27 (9):709-720 Epub 2018 Aug 30
    View PubMed
  122. Huffman BM, Westin G, Alsidawi S, Alberts SR, Nagorney DM, Halfdanarson TR, Mahipal A. Survival and Prognostic Factors in Patients With Solid Pseudopapillary Neoplasms of the Pancreas. Pancreas. 2018 Sep; 47 (8):1003-1007
    View PubMed
  123. DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ. Novel immunotherapy strategies for hepatobiliary cancers. Immunotherapy. 2018 Sep; 10 (12):1077-1091
    View PubMed
  124. Jin Z, Hartgers ML, Sanhueza CT, Shubert CR, Alberts SR, Truty MJ, Muppa P, Nagorney DM, Smyrk TC, Hassan M, Mahipal A. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience. Eur J Surg Oncol. 2018 May; 44 (5):677-683 Epub 2018 Feb 16
    View PubMed
  125. Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers (Basel). 2018 Jan 20; 10 (1)
    View PubMed
  126. Chaker M, Minden A, Chen S, Weiss RH, Chini EN, Mahipal A, Azmi AS. Rho GTPase effectors and NAD metabolism in cancer immune suppression. Expert Opin Ther Targets. 2018 Jan; 22 (1):9-17 Epub 2017 Dec 10
    View PubMed
  127. Huffman B, Westin G, Mahipal A. Survival analysis of patients with solid pseudopapillary tumors of the pancreas in a multicenter retrospective cohort. Ann Oncol. 2017 Jun; 28 Suppl 3:iii137
    View PubMed
  128. Kim DW, Byer J, Kothari N, Mahipal A, Chang YD, Kim RD. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. Oncology. 2017; 92: (4)190-196.
    View PubMed
  129. Thompson SM, Zendejas-Mummert B, Hartgers ML, Venkatesh SK, Smyrk TC, Mahipal A, Smoot RL. Malignant transformation of biliary adenofibroma: a rare biliary cystic tumor. J Gastrointest Oncol. 2016 Dec; 7 (6):E107-E112
    View PubMed
  130. Mahipal A, Grothey A. Role of Biologics in First-Line Treatment of Colorectal Cancer. J Oncol Pract. 2016 Dec; 12 (12):1219-1228
    View PubMed
  131. Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016 Sep 19;
    View PubMed
  132. Mahipal A, Malafa M. Importins and exportins as therapeutic targets in cancer. Pharmacol Ther. 2016 Aug; 164:135-43 Epub 2016 Apr 23
    View PubMed
  133. Mahipal A, Klapman J, Vignesh S, Yang CS, Neuger A, Chen DT, Malafa MP. Pharmacokinetics and safety of vitamin E delta-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites. Cancer Chemother Pharmacol. 2016 Jul; 78: (1)157-65.
    View PubMed
  134. Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, Kauffman M, Shacham S, Mahipal A. First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 Feb 29;
    View PubMed
  135. Mahipal A, Shibata D, Siegel E, Almhanna K, Springett G, Fulp W, Williams-Elson I, Kim R. Phase I Trial of Combination of FOLFIRI and Pasireotide, a Somatostatin Analogue, in Advanced Gastrointestinal Malignancies. Investigational New Drugs.2016;33:(5)1093-9.
  136. Sajjad M, Batra S, Hoffe S, Kim R, Springett G, Mahipal A. Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis. Am J Clin Oncol. 2016 Jan 19;
    View PubMed
  137. Ambe CM, Mahipal A, Fulp J, Chen L, Malafa MP. Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature. PLoS One. 2016; 11: (3)e0151632.
    View PubMed
  138. Kim R, Prithviraj G, Kothari N, Springett G, Malafa M, Hodul P, Kim J, Yue B, Morse B, Mahipal A. PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer. Clin Nucl Med. 2015 Nov; 40: (11)e501-5.
    View PubMed
  139. Denson A, Burke N, Wapinsky G, Bertels B, Juan TH, Lee J, Springett GM, Strosberg JR, Kim RD, Sullivan DM, Mahipal A. Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol. 2015 Oct 29;
    View PubMed
  140. Mahipal A, Frakes J, Hoffe S, Kim R. Management of borderline resectable pancreatic cancer. World J Gastrointest Oncol. 2015 Oct 15; 7: (10)241-9.
    View PubMed
  141. Mahipal A, Choi M, Kim R. Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand? J Natl Compr Canc Netw. 2015 Oct; 13: (10)1281-91; quiz 1292.
    View PubMed
  142. Suleiman Y, Mahipal A, Shibata D, Siegel EM, Jump H, Fulp WJ, Springett GM, Kim R. Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2015 Sep; 76: (3)481-7.
    View PubMed
  143. Ambe C, Fulp W, Springett G, Hoffe S, Mahipal A. A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. J Gastrointest Cancer. 2015 Sep; 46: (3)284-90.
    View PubMed
  144. Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A. Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer. Molecular Cancer Therapeutics.2015;14:(7)1570-81.
  145. Papadopoulos KP, Isaacs R, Bilic S, Kentsch K, Huet HA, Hofmann M, Rasco D, Kundamal N, Tang Z, Cooksey J, Mahipal A. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody(R) targeting the DR5 receptor. Cancer Chemother Pharmacol. 2015 May; 75: (5)887-95.
    View PubMed
  146. Saneeymehri SS, Markey KR, Mahipal A. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review. J Oncol Pharm Pract. 2015 Apr 6;
    View PubMed
  147. Mahipal A, Denson AC, Djulbegovic B, Lush R, Kumar A, Juan TH, Schell MJ, Sullivan DM. Effect of Age on Clinical Outcomes in Phase 1 Trial Participants. Cancer Control.2015;22:(2)235-41.
  148. Mahipal A, Nguyen D. Risks and benefits of phase 1 clinical trial participation. Cancer Control. 2014 Jul; 21: (3)193-9.
    View PubMed
  149. Mahipal A. Clinical trials and drug development. Cancer Control. 2014 Jul; 21: (3)188-9.
    View PubMed
  150. Denson AC, Mahipal A. Participation of the elderly population in clinical trials: barriers and solutions. Cancer Control. 2014 Jul; 21: (3)209-14.
    View PubMed
  151. Riaz W, Burke N, Mahipal A. Selinexor. Exportin-1 (XPO1) inhibitor, Oncolytic. Drugs of the Future.2014;39:(10)685.
  152. Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology. 2014; 87: (2)125-32.
    View PubMed
  153. Mahipal A, Kothari N, Gupta S. Epidermal growth factor receptor inhibitors: coming of age. Cancer Control. 2014 Jan; 21: (1)74-9.
    View PubMed
  154. Ashraf N, Mahipal A, Kim R. Viral Vector Vaccines To Treat Colorectal Cancer. Curr Colorectal Cancer Rep.2013;9:398-405.
  155. Kim R, Mahipal A, Choi M, Saif MW. Biomarkers for pancreatic cancer: is it ready for primetime? JOP. 2013 Jul; 14: (4)309-11.
    View PubMed
  156. Gupta S, Mahipal A. Role of systemic chemotherapy in urothelial urinary bladder cancer. Cancer Control. 2013 Jul; 20: (3)200-10.
    View PubMed
  157. Mahipal A, Mitchell E. Gemcitabine, Oxaliplatin and Bevacizumab in patients with biliary tract cancers. Journal of Solid Tumors.2013;3:(3)29.
  158. Mahipal A, Tijani L, Chan K, Laudadio M, Mastrangelo MJ, Sato T. A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res. 2012 Dec; 22: (6)440-6.
    View PubMed
  159. Mahipal A, Mcdonald MJ, Witkiewicz A, Carr BI. Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma. Med Oncol. 2012 Mar; 29: (1)134-9.
    View PubMed
  160. Sbenghe MM, Besa E, Mahipal A, Dulau Florea A, Bray P, Caro J. HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease. Oncologist. 2012; 17: (1)145-6; author reply 147-8.
    View PubMed
  161. Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ, Sato T. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother. 2011 Jul; 60: (7)1039-45.
    View PubMed
  162. Mahipal A, Gupta S. Small-cell carcinoma of the gallbladder: report of a case and literature review. Gastrointest Cancer Res. 2011 Jul; 4: (4)135-6.
    View PubMed
  163. Mahipal A, Weiss M. The addition of rituximab to fludarabine and cyclophosphamide improves progression-free survival in patients with previously treated chronic lymphocytic leukemia. Curr Oncol Rep. 2010 Nov; 12: (6)352-4.
    View PubMed
  164. Gupta S, Mahipal A. A case of acquired hemophilia associated with bullous pemphigoid. Am J Hematol. 2007 Jun; 82: (6)502.
    View PubMed
  165. Mahipal A, Bilgrami S. Acquired hemophilia in chronic lymphocytic leukemia. Leuk Lymphoma. 2007 May; 48: (5)1026-8.
    View PubMed
  166. Gupta S, Mahipal A. Fatal pulmonary toxicity after a single dose of cyclophosphamide. Pharmacotherapy. 2007 Apr; 27: (4)616-8.
    View PubMed
  167. Mahipal A, Anderson KE, Limburg PJ, Folsom AR. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev.2006;15:(10)1785-90.
  168. Mahipal A, Anderson KE, Limburg PJ, Folsom AR. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev. 2006 Oct; 15: (10)1785-90.
    View PubMed
  169. Swenson KK, Mahipal A, Nissen MJ, Tuttle TM, Heaton K, Lally RM, Spomer A, Lee MW. Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma. Cancer. 2005 Nov 1; 104: (9)1834-9.
    View PubMed